Supports urogenital health: RC-14™ and GR-1™ at 1 billion CFU each day significantly enhanced the vaginal microbiome composition after just 60 days compared with the placebo. 1 At day 35, 94% of the probiotic group saw a substantial increase in health-promoting lactobacilli populations, while 24% of the placebo group developed bacterial vaginosis. Furthermore, 30 days after the trial ended, those who had been taking the probiotics still maintained a healthier vaginal microbiome compared to the placebo group.
Regulate bowel movements: Both BB-12™ and CLEPIUS™ Lpla33™ support regular bowel movements. Taking BB-12™ at a daily dose of 1 billion CFU significantly increased the frequency of bowel movements in healthy adults with low defecation frequency over 4 weeks, compared to a placebo group. 2 At the other end of the spectrum, participants with diarrhoea dominant IBS who took 1 billion CFU of CLEPIUS™ Lpla33™ daily for 8 weeks saw a remarkable reduction in IBS symptom severity. 3 Impressively, 62% of the group reported over a 50% decrease in mushy or watery stools compared to the placebo group.
Decreases abdominal discomfort, distention, and bloating: Taking CLEPIUS™ Lpla33™ at 1 billion CFU daily led to an impressive 42% reduction in the severity of abdominal discomfort and a 44% reduction in bloating compared to those in the placebo group.3 Additionally, their quality of life scores soared by 60% over the eight weeks, highlighting the significant positive impact of the probiotic.
Promote immune health and emotional well-being: BB-12™ boosts immunity against respiratory viruses. Compared with the placebo group healthy participants who took 1 billion CFU daily of BB-12™ for six weeks had a significant increase in immunoglobulin (Ig) G and IgA, important first line and mucosal defences, after receiving the influenza vaccine.4 Stress, among other factors, can dampen immune responses. Supplementation with probiotic strain CLEPIUS™ Lpla33™, at a dose of 1 billion CFU over eight weeks, significantly lowered stress levels by 19% compared to the placebo.
